Results 81 to 90 of about 7,987 (192)

Radiotherapy and Immunotherapy In Hepatocellular Carcinoma: Priming the Tumor Immune Microenvironment From Bench To Bedside

Precision Radiation Oncology, Volume 10, Issue 3, Page 417-427, September 2026.
The dual immunomodulatory network of radiotherapy in hepatocellular carcinoma. Radiotherapy initiates its effects by inducing immunogenic cell death and DNA double‐strand breaks. Immune Activation: Cytosolic DNA from damaged cells activates the cGAS‐STING pathway, triggering IRF3/NF‐κB‐mediated type I interferon production. This enhances dendritic cell
Zhigang Fu, Yang Zhang, Zuomin Wang, Zongjuan Li, Shisuo Du   +4 more
wiley   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC)

, 2022
PURPOSE: Management of progressive, metastatic radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) has been a great challenge due to its poor prognosis and limited treatment options.
Shi, Liang, Yao, Xiaocheng, Lin, Yansong, Li, Shuren, Wang, Hanjin, Li, Shaohua, Wu, Wenyu, Zhang, Lele, You, Qinqin, Wang, Jun, Tian, Rui, Wang, Feng   +11 more
core   +1 more source

Efficacy and safety of camrelizumab combined with apatinib as second‐line and beyond treatment for advanced combined hepatocellular‐cholangiocarcinoma

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Camrelizumab plus apatinib demonstrated promising efficacy (ORR 20.0%, DCR 72.0%, mOS 12.5 months, mPFS 4 months) and excellent tolerability (no grade ≥3 TRAEs) as second‐line and beyond therapy for advanced cHCC‐CCA, with CA19‐9 dynamics identified as a potential early surrogate biomarker for treatment response.
Haiyun Geng, Fang Dai, Kuimin Mei, Mengran Cao, Haiqing Hua, Xinlei Gong   +5 more
wiley   +1 more source

Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil

, 2019
Zhiyuan Xu,1,* Can Hu,2,* Shangqi Chen,2 Chunli Zhang,3 Jianfa Yu,4 Xiaofeng Wang,2 Hang Lv,5 Xiangdong Cheng11Department of Abdominal Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People’s Republic of China; 2First Clinical Medical ...
Hu C, Lv H, Wang X, Chen S, Zhang C, Yu J, Cheng X, Xu Z   +7 more
core  

Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters

, 2010
Apatinib, a small-molecule multitargeted tyrosine kinase inhibitor, is in phase III clinical trial for the treatment of patients with non–small-cell lung cancer and gastric cancer in China.
Fang Wang, Amit K. Tiwari, Hong-bing Huang, Suresh V. Ambudkar, Hong-yun Zhao, Chung-Pu Wu, Yan-jun Mi, Li-yang Tao, Li-wu Fu, Chuan-zhao Zhang, Chun-Ling Dai, Xiao-xu Ma, Yong-ju Liang, Kenneth Kin Wah To, Zhe-Sheng Chen   +14 more
core   +1 more source

Photodynamic Biomimetic Nanoparticles Accelerate Tumor Vascular Normalization Initiation

Exploration, Volume 6, Issue 4, August 2026.
Platelet‐mimetic IA@PM integrates apatinib‐driven vascular normalization with ICG‐mediated photodynamic therapy, creating a self‐amplifying vascular normalization therapy (VNT)–photodynamic therapy (PDT) cycle that accelerates the onset of the vascular normalization window and potentiates antitumor treatment.
Yufei Liu, Changheng Xie, Yanfeng Huang, Ting Wang, Shi Du, Hui Xiong, Jing Yao   +6 more
wiley   +1 more source

Apatinib-loaded nanoparticles suppress vascular endothelial growth factor-induced angiogenesis and experimental corneal neovascularization

, 2017
Jung Eun Lee,1,* Koung Li Kim,2,* Danbi Kim,2 Yeongju Yeo,2 Hyounkoo Han,3 Myung Goo Kim,1,4 Sun Hwa Kim,4 Hyuncheol Kim,3,5 Ji Hoon Jeong,1,4 Wonhee Suh2 1School of Pharmacy, Sungkyunkwan University, Suwon, 2College of Pharmacy, Chung-Ang University ...
Kim D, Lee JE, Jeong JH, Kim SH, Kim H, Suh W, Kim KL, Yeo Y, Han H, Kim MG   +9 more
core  

Glucose Transporter 1 in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
As the quintessential facilitator of basal glucose uptake, glucose transporter 1 (GLUT1) is indispensable for maintaining systemic energy homeostasis. This graphical abstract delineates the multidimensional landscape of GLUT1 in normal physiology. It highlights its tissue‐specific metabolic roles—from fueling erythrocytes and fetal development to ...
Yi Tai, Zhihao Chen, Yuping Zhu, Weidong Han   +3 more
wiley   +1 more source

Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage

, 2016
Ji Hoon Jeong,1,* Hong Khanh Nguyen,2,* Jung Eun Lee,1 Wonhee Suh2 1School of Pharmacy, Sungkyunkwan University, Suwon, 2College of Pharmacy, Chung-Ang University, Seoul, Korea *These authors contributed equally to this work Abstract: Apatinib, a
Jeong JH, Lee JE, Nguyen HK, Suh W
core